MTD › analyze
MTD · Analyze
Context: MTD is a nomination for the 🏛 Evergreen Compounders sleeve (Watchlist.md line 25/467), not yet tracked. This report evaluates whether it earns a sleeve line against the sleeve's current weakest members, PCTY [5.5] HOLD and IBM [5.5] HOLD.
0. Knowledge-base check
python .mcp/kb.py find MTD and find instruments returned no matches — nothing previously known on this name; researched fresh. Two data-quality pitfalls fired during this analysis and materially shaped the write-up:
- [[pitfall-yahoo-book-value-lags-buyback-equity-collapse]] — Yahoo/vendor book-value fields are unreliable after aggressive buybacks.
- [[pitfall-fin-py-snapshot-mixes-annual-and-mrq-dates]] —
fin.py's snapshot ratios (BVPS, P/B, D/E) are price-derived and can disagree with the annual statement block.
MTD's case is a third, related but distinct shape: this is not a lag artifact from one recent event — shareholders' equity has been structurally negative for years (2023: −$149.9M, 2024: −$126.9M, 2025: −$23.6M) from over a decade of buybacks exceeding retained earnings. Any vendor field built on book value is unusable here, not stale — permanently broken by design. Confirmed independently via .mcp/fin.py (BVPS $0.64, P/B 2,001, D/E 16,668) and roic.ai (P/B −1,201x FY25, P/TangBV −27.2x, com_eqy/assets −0.64%). Do not use P/B, BVPS, D/E, or Graham IV for this name — use Debt/Assets (57.97%, cross-validated identically by both sources) for leverage instead.
roic.ai also hit [[pitfall-roicai-free-plan-caps-history-at-two-years]] — requests for 8yr history returned only FY2024–FY2025. Multi-year trend below is fin.py's 4-year annual window (2022–2025); a true 5–8yr CAGR was not available without an SEC XBRL escalation, which was not run given the sleeve-nomination scope. This caps confidence on the FCF CAGR specifically — flagged, not silently assumed.
1. Fundamentals (Health)
| Metric | 2022 | 2023 | 2024 | 2025 | 3yr CAGR |
|---|---|---|---|---|---|
| Revenue | $3.92B | $3.79B | $3.87B | $4.03B | +0.9% |
| Gross margin | 58.9% | 59.1% | 60.1% | 59.4% | ~flat |
| Op margin | 28.8% | 28.5% | 29.1% | 27.8% | −100bp |
| Net income | $872.5M | $788.8M | $863.1M | $869.2M | −0.1% |
| EPS (diluted, GAAP) | $38.41 | $35.90 | $40.48 | $42.05 | +3.1%/yr |
| OCF | $859.1M | $965.9M | $968.4M | $955.8M | +3.6% |
| FCF | $737.8M | $860.6M | $864.5M | $848.7M | +4.8%* |
| Buybacks | $1.10B | $900M | $850M | $800M | −12.4%/yr |
| Diluted shares | 22.72M | 21.97M | 21.32M | 20.67M | −3.1%/yr |
| FCF/share | $32.48 | — | — | $41.05 | +8.1%/yr |
FCF's 3yr CAGR is flattered by a low 2022 base; FCF has been flat at $848–865M for three straight years (2023→2025)*, not compounding. FCF/share still compounds at ~8%/yr — entirely a function of the share count shrinking faster than aggregate cash flow is growing.
Capital allocation: near-100% of FCF returned via buybacks, zero dividend (payout ratio 0%). This is a pure capital-appreciation compounder, not an income vehicle — relevant given the user's shift toward balanced growth + income; MTD fills the growth/quality role, not the income role. Buyback pace has decelerated three years running (−$1.10B → −$800M, −27% cumulative) even as the share price sits mid-range — the opposite of "buy more when cheap." In years the buyback exceeded FCF (2022: $1.10B buyback vs $737.8M FCF), the gap was debt-funded — the mechanism behind the chronic negative equity, not a one-off ASR shock like CRM's.
Leverage: Net debt/EBITDA 1.70x (2025, down slightly from 1.59x 2024), EBITDA/interest 17.9x, Debt/Assets 57.97%. Coverage is strong; the balance sheet has room to keep funding buybacks, but not unlimited room — it is already running at negative equity.
Insider activity: CFO and one director both executed same-day option exercise-and-sell transactions in early August 2026 (~$3.2M and ~$600K respectively) after a strong Q2 print. These are non-discretionary compensation liquidations at deep in-the-money strikes ($595 and $398 vs a ~$1,430 stock), not open-market conviction sales — noted for completeness, not treated as a bear signal.
Scorecard: solid, not exceptional. Margins are stable, leverage is manageable, and per-share metrics compound nicely — but that compounding is now almost entirely a buyback effect on a top-line and bottom-line that have been flat for three years until this year's recovery. This is adjacent to [[pattern-buyback-manufactured-eps-screens-as-growth]] — not a full match (FCF/share is genuinely growing, not purely accounting optics), but the mechanism is the same and the dependency on continued repurchases is real.
2. Moat
- Quantitative base: ROIC (roic.ai, invested-capital basis) 41.7% (2025), down from 43.9% (2024) — best-in-class by a wide margin, ROA 25%, return on capital 46%. Gross margin stable at 59–60% for four years — no erosion. The ~2pt ROIC compression and ~100bp op-margin compression in 2025 are worth watching but are single-year moves, not a trend yet.
- Revenue-stream map: instruments (balances, pipettes, process analytics, product inspection) sold with high switching costs into regulated (GxP) pharma/lab environments, where re-validating a new instrument is itself a costly, auditable process. Service + consumables have grown from ~high-teens to ~24–25% of revenue over the past decade (sources vary 22–35% depending on definition; the consistent recent figure is ~24-25%) — a genuine, growing razor/blade annuity layered on the installed base.
- Adversarial stress-test: Thermo Fisher competes on breadth/bundling and pressures lab standardization; Danaher (Beckman Coulter, Hach) overlaps in process analytics and water monitoring; Sartorius is the stronger bioprocessing/bioproduction competitor; Shimadzu/Keyence compete at the commoditized end of weighing/vision. No rival has displaced MTD's core calibration-critical balance/weighing niche — the compliance/requalification cost is the moat. The genuine pressure point is bioprocessing, where Sartorius and Danaher are stronger, and the general-instrumentation commoditization Redburn flags at the low end.
- China/pharma exposure — a real, two-sided lever, not a one-way risk. 2023's revenue dip coincided with a well-documented China anti-corruption-driven capex freeze on lab/pharma spending. Q2 2026 showed China +9% (industrial double-digit), three consecutive quarters of acceleration, helped by a Chinese Pharmacopeia regulatory tailwind, and management raised the full-year local-currency growth guide to 4–5%. This cuts both ways: it explains both the 2023 trough and the 2026 recovery, and it means MTD's growth is lumpier than a typical staples-style evergreen name.
- Disruption forecast (5–10yr): low existential risk in the regulated core (compliance moat is durable); the real risk is margin/pricing pressure at the commoditized low end of general lab instrumentation, which is Redburn's explicit bear case, not a technology displacement thesis.
- Evergreen assessment: yes. Essential, non-discretionary QC/production-line demand, wide and durable moat in the regulated core, disruption risk is real but gradual rather than structural. Classic evergreen-compounder shape.
3. Valuation
| Value | |
|---|---|
| Price (2026-09-10) | $1,281 |
| 52wk range | $1,023 – $1,525 |
| 5yr range (quarterly closes) | ~$930 – ~$1,720 |
| PE (ttm) | 28.85x |
| PE (fwd) | 24.77x |
| EV/EBITDA (ttm) | 21.75x |
| Own 2yr PE band (roic.ai, trailing) | ~22x (low) – ~38x (high), avg ~30-33x |
| Own 2yr EV/EBITDA band | ~17x (low) – ~33x (high), avg ~23x |
| Consensus target (mean) | $1,452 (+13.4%) |
| Redburn (Sell, initiated 9/2) | $1,200 target, flags 27x FY27 EPS as a 17% premium to S&P life-sci tools peers |
Graham IV: not usable — structurally negative/near-zero book value (see §0). DYT/DDM: N/A — no dividend. Bogle's expected return: with 0% yield, return = earnings growth ± multiple change. GAAP EPS growth has run only ~3%/yr (flat top line 2022–2025); analyst adjusted EPS growth is faster (~+10.7% 2026e, +8.7% 2027e per Redburn) on the China/pharma recovery. If the multiple holds flat, that implies a high-single-digit to low-double-digit expected return; if it mean-reverts toward the cheaper end of its own 2yr band (~22x), that's an offsetting ~10%+ headwind — netting to a "fair, not fantastic" expected return, not a screaming value case.
Since Redburn's Sell call (published near ~$1,387), the stock has already fallen ~7.6% to $1,281 — within 6.7% of Redburn's own $1,200 target — meaning a meaningful slice of the bear case is already in the price. Against that, Q2 2026 beat, a raised organic growth guide, and a Zacks upgrade to Buy on rising estimates argue the deceleration/commoditization thesis is not yet showing up in the numbers.
Fair value range: $1,100–$1,420 (built off 2026 consensus EPS ~$47.29 across a 22x–30x band — the low end near this cycle's trough multiple, the high end below Redburn's flagged "premium" zone). Spot $1,281 sits roughly at the midpoint of its own band — fairly valued, not cheap. Entry zone for a fresh position: $1,050–1,150 (near 52wk-low support, ~22x). Trim: 30x fwd (≈$1,420 at current fwd EPS, near the 52wk high) — set as a multiple per the Valuation Analyst rule so it tracks the live EPS base rather than freezing a dollar level.
4. Sentiment
Split sell-side picture: Redburn initiated Sell (9/2) on valuation-outpacing-growth grounds — mature end markets, commoditization, China risk, even while explicitly conceding "best-in-class returns... ~28% ROIC... strong brand... large installed base." Zacks upgraded to Buy on rising consensus estimates following the Q2 beat and raised guide. StockStory's Q2 teardown and Barchart's analyst-coverage roundup are more neutral/mixed. Insider activity (§1) is routine compensation liquidation, not a signal either way. Net read: a genuine, live analyst split — not a consensus in either direction — which is itself informative: this is a name where reasonable analysts disagree on whether the ROIC is durable enough to justify the multiple, exactly the tension the fundamentals in §1 surface (flat aggregate FCF vs. compounding FCF/share).
5. Synthesis & Verdict
§1 health bar: Pass, with a caveat. Margins stable, leverage manageable and well-covered, ROIC elite (41-44%) — but aggregate revenue/FCF/net income have been flat for three years, and the compounding story now runs almost entirely through a decelerating buyback. Good business, not currently a growth story.
Buy zone or watch? WATCH. Spot ($1,281) sits near the midpoint of its own valuation band, not in the $1,050–1,150 entry zone. Great company, fair-to-full price — per analysis_notes.md §0, that's "wait," not "value."
Does it beat the sleeve's weakest members (PCTY/IBM, both [5.5] HOLD)? Yes, on business quality. MTD's ROIC (~42%) is roughly 4x IBM's (~10.5%, falling), its gross margin is stable where IBM's software growth was purchased and PCTY's NRR is softening (92%, from a decelerating 22.7%→~7% growth trajectory). MTD's core regulated-instrument moat (compliance/requalification switching costs) is harder to attack than IBM's software stack or PCTY's payroll SaaS platform, both of which face active platform-switching pressure (Rippling/Dayforce/UKG for PCTY; hyperscalers/AI-native tools for IBM). MTD also returns cash more cleanly (100% FCF via buybacks, no dividend-growth-is-dead problem like IBM's penny-a-year raises) — though it offers zero income, which IBM and PCTY at least partially do or historically did. On valuation, though, MTD is not the bargain IBM/PCTY currently are near their bands — it's a quality premium, not a cheap one.
Proposed sleeve + conviction: 🏛 Evergreen Compounders, conviction [6.5]. This is above PCTY/IBM's [5.5] — it earns the sleeve line — and in line with the sleeve's other WATCH-band names (STZ [6.5], OLED [6.5]), both wide-moat names priced for a defined entry rather than bought today.
Biggest risk: A high-multiple (~25-29x), structurally negative-equity, zero-dividend compounder whose own operating income and FCF have been flat for three years, now priced for the 2026 China/pharma reacceleration to hold. If that reacceleration proves as cyclical as the 2023 downturn that preceded it — while the multiple is still mid-band, not trough — Redburn's Sell case plays out with real downside, and the decelerating buyback pace (−27% over three years) means the per-share growth engine that has carried the stock has less fuel than it did.
Sources: .mcp/fin.py MTD --news, roic.ai (profitability/valuation/credit ratios, NYSE:MTD), Yahoo Finance MCP (historical prices), WebSearch (Redburn initiation via Investing.com/Daily Political, Q2 2026 earnings call via Motley Fool/Yahoo, insider transactions via Motley Fool/MarketBeat, competitive landscape via Comparably/PitchGrade/MatrixBCG, service-revenue mix via bizmodelmastery Substack — cross-checked against a 22-35% range, reported conservatively at ~24-25%).